Surface Chemistry for Biosensors, Nanoparticles, Imaging and Microfluidics, Specialty Fine Chemicals as well as Therapeutics for Photodynamic Therapy.


Photodynamic therapy (PDT), the treatment of disease with light and a light-activated therapeutic agent, has made strides towards a more general clinical acceptance over the past decade, but still has not reached the stage where it is recognized as a first line or primary treatment for solid subcutaneous cancerous tumors by most clinicians, including most surgeons and radiation oncologists. Until now.

the   future

In a newly proposed extension of the Phase II contract, we will use Image-guided targeted two-photon photodynamic therapy (TTPDT) to develop a turn-key outpatient treatment for recurring refractory head and neck cancer that will replace current debilitating cancer treatments.

forward  thinking

Brenda D Spangler, PhD Chief Executive Officer
Charles W Spangler, PhD Chief Scientific Officer

Brenda Spangler has over 30 years experience in the field of protein chemistry and protein toxins, specializing in ligand-receptior molecular recognition - Read more in the 'About' section.

Charles Spangler has been working in the area of design and synthesis of highly conjugated organic materials for more than 30 years. His group has been involved with the design, synthesis, and characterization of new organic optical power limiting materials for eye and sensor protection, becoming one of the leaders in the design of new chromophores and dendrimers exhibiting reverse saturable absorption (RSA) and enhanced two-photon absorption (TPA) - Read more in the 'About' section.

What`s   New?

Cancer Research

SensoPath is completing a $1.5 M, 2 year NIH/National Cancer Institute SBIR contract award in collaboration with the University of Florida Dpartment of Biomedical Engineering and the School of Veterinary Medicine for development of our Targeted Two-Photon Photodynamic Therapy therapeutic and imaging system followed by animal trials.